Printer Friendly

Proneuron Biotechnologies Announces Initiation of Phase 1 Clinical Trial in Complete Spinal Cord Injury.

Business Editors and Health/Medical Writers

BIOWIRE2K

NESS-ZIONA, ISRAEL--(BW HealthWire)--July 31, 2000

First Patient Treated with Activated Macrophage Therapy for

Nerve Regeneration

Proneuron Biotechnologies, a privately-held company, today announced the enrollment of the first patient in a Phase 1 study to assess the safety of autologous activated macrophage therapy in the treatment of patients with complete spinal cord injury. The study, conducted in Israel under a US Food and Drug Administration Investigational New Drug Application and with the approval of the Israel Ministry of Health, is designed to study approximately eight complete spinal cord injury patients and follow their post-treatment course for one year or longer.

The use of autologous activated macrophages for nerve regeneration is based on technology developed in the laboratory of Prof. Michal Schwartz, Weizmann Institute of Science, Israel and licensed to Proneuron. Prof. Schwartz and her team study the role of immunity within the central nervous system in the development of neurological disorders. Her research has demonstrated significant recovery of neurological function in animal models of spinal cord injury by activating and administering macrophages, a type of immune cell.

Macrophages are white blood cells that play a beneficial role in wound healing and tissue regeneration throughout the body. However, within the central nervous system (CNS), macrophage activity appears to be naturally diminished and the brain and spinal cord are incapable of spontaneous regeneration. The strategy employed in this present trial is to induce nerve regeneration by enhancing the natural macrophage response in injured spinal cord tissue by directly implanting activated autologous cells (taken from the patient himself/herself). If the positive results of extensive animal experiments can be repeated in humans, the use of this therapeutic approach would be of significant clinical value even if only partial recovery can be achieved.

Dr. Nachshon Knoller, Senior Neurosurgeon, Sheba Medical Center, Tel Hashomer, Israel, a principal investigator in this study commented, "In view of the impressive published preclinical results obtained with autologous activated macrophages, I am pleased to have performed the first such human procedure to test the safety of the technique. Complete spinal cord injury is a devastating neurological condition and therapies aimed at spinal cord regeneration are vitally needed."

In the current study, adults with complete lower cervical (C5-7) or thoracic (T1-T10) spinal cord injury who meet specified inclusion and exclusion criteria are eligible if they can be treated within 14 days of their injury. Macrophages are harvested from the patient, activated in a special facility by Proneuron scientists and implanted surgically by one of the participating neurosurgeons. Following this procedure, patients will be intensively followed with safety monitoring and periodic assessments of clinical, radiographic and electrophysiological parameters. If results, which are not expected earlier than 9 to 12 months from the time of treatment, support additional clinical testing, a Phase 2 study will be initiated.

Proneuron Biotechnologies is a biopharmaceutical company developing therapeutic products for the treatment of acute and chronic diseases of the central nervous system based on proprietary technology for modulating the interaction between the nervous and the immune systems.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 31, 2000
Words:509
Previous Article:Cedar Group Growth Reflected in Rising Top 500 Software Ranking; Enterprise Business Solutions Vendor Moves Up In Rankings; Hires PR Agency To Help...
Next Article:Gartner Says Record Industry Will Severely Damage Itself by Getting What it Wishes for in Court Ruling Against Napster.
Topics:


Related Articles
Immune attack on self halts nerve damage.
PRONEURON STARTS 2ND PHASE 1 SPINAL CORD INJURY CLINICAL TRIAL.
PRONEURON/CRAIG HOSPITAL TO DEVELOP MACROPHAGE THERAPY FOR SCI.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters